Suppression of Epidermal Growth Factor Receptor by Erlotinib Attenuates Carvacrol-induced Skin Inflammation by Yujing Wang, Wenjie Huang, Haidong Jia, Qinglian Tang, Qingfei Yin, Yuanyuan Chen, Wumei Wang, Zhengyu Cao

Subjects: Get full text

Erlotinib Improves the Response of Glioblastoma Cells Resistant to Photodynamic Therapy by Karen Olthoff, Ayelén D. Nigra, Laura N. Milla Sanabria

Subjects: Get full text

Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review) by O.M. Smorodska, Yu.V. Moskalenko, I.O. Vynnychenko, O.I. Vynnychenko, V.V. Kostuchenko

Subjects: Get full text

Upregulated interleukin‐6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma by Aditya Stanam, Laurie Love-Homan, Tisha S. Joseph, Madelyn Espinosa-Cotton, Andrean L. Simons

Subjects: Get full text

Erlotinib therapy for Olmsted syndrome with p.L655P missense mutation in the TRPV3 gene: a case report by Jia Zhang, MengYue Guo, DongYang Yuan, JinYang Wei, Hongzhou Cui, Hongzhou Cui

Subjects: Get full text

Synergistic activity of Pitstop-2 and 1,6-hexanediol in aggressive human lung cancer cells by Sílvio Terra Stefanello, Caren Rigon Mizdal, Aline Franzen da Silva, Luca Matteo Todesca, Félix Alexandre Antunes Soares, Victor Shahin

Subjects: Get full text

Bufadienolides from Chansu Injection Synergistically Enhances the Antitumor Effect of Erlotinib by Inhibiting the KRAS Pathway in Pancreatic Cancer by Yanli Guo, Yu Jin, Jie Gao, Ding Wang, Yanming Wang, Liya Shan, Mengyu Yang, Xinzhi Li, Ketao Ma

Subjects: Get full text

Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Ad... by Yan-Jei Tang, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu

Subjects: Get full text

Review of pharmacological interactions of oral anticancer drugs provided at pharmacy department by E. Sánchez Gómez, Y. Arco Prados

Subjects: “…Tyrosine kinase inhibitors (particularly Erlotinib…”